These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9736424)

  • 21. [Therapeutic trial with fucidin in systemic scleroderma].
    Rubisz-Brzezińska J; Zebracka T; Mozdzanowski J; Mozdzanowska K
    Z Hautkr; 1984 Dec; 59(23):1611-9. PubMed ID: 6395525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls.
    Antonelli A; Ferri C; Ferrari SM; Mancusi C; Colaci M; Sebastiani M; Fallahi P
    Scand J Rheumatol; 2011 Nov; 40(6):453-6. PubMed ID: 21722069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parallel induction of fibrinolysis and receptors for plasminogen and urokinase by interferon gamma on U937 cells.
    Lu H; Mirshahi M; Krief P; Soria C; Soria J; Mishal Z; Bertrand O; Perrot JY; Li H; Picot C
    Biochem Biophys Res Commun; 1988 Aug; 155(1):418-22. PubMed ID: 2843185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of excessive scleroderma fibroblast collagen production by recombinant gamma-interferon. Association with a coordinate decrease in types I and III procollagen messenger RNA levels.
    Rosenbloom J; Feldman G; Freundlich B; Jimenez SA
    Arthritis Rheum; 1986 Jul; 29(7):851-6. PubMed ID: 3091039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers.
    Usmani N; Murphy A; Veale D; Goulden V; Goodfield M
    Clin Exp Dermatol; 2010 Aug; 35(6):608-13. PubMed ID: 19874362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous fibrinolytic activity in scleroderma.
    Lotti T; Cerinic MM; Marmugi D; Fabbri P
    Clin Exp Rheumatol; 1985; 3(3):249-53. PubMed ID: 4053443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic sclerosis.
    Ng SC
    Singapore Med J; 1992 Apr; 33(2):189-92. PubMed ID: 1621127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical, serological, and immunogenetic studies of systemic sclerosis.
    Maddison PJ
    Rev Rhum Mal Osteoartic; 1991 May; 58(5):369-70. PubMed ID: 1905420
    [No Abstract]   [Full Text] [Related]  

  • 29. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.
    Jayson MI; Holland CD; Keegan A; Illingworth K; Taylor L
    Ann Rheum Dis; 1991 Jan; 50(1):41-7. PubMed ID: 1994867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.
    Needleman BW; Wigley FM; Stair RW
    Arthritis Rheum; 1992 Jan; 35(1):67-72. PubMed ID: 1731816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts.
    Antonelli A; Ferri C; Ferrari SM; Colaci M; Giuggioli D; Fallahi P
    Br J Dermatol; 2010 Sep; 163(3):650-1. PubMed ID: 20456349
    [No Abstract]   [Full Text] [Related]  

  • 32. Cutaneous and plasma fibrinolytic activities are not deficient in patients with systemic sclerosis.
    Lotti T; Campanile G; Matucci-Cerinic M
    J Am Acad Dermatol; 1994 May; 30(5 Pt 1):813-4. PubMed ID: 8176033
    [No Abstract]   [Full Text] [Related]  

  • 33. [The blood coagulation system in progressive systemic scleroderma].
    Sica S; Paoletti S; Storti S; Pagano L; Marra R; Garcovich A
    Minerva Med; 1987 Dec; 78(24):1831-4. PubMed ID: 2448705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Blood fibrinolytic activity in various diseases (periarteritis nodosa, dermatomyositis, scleroderma). Preliminary communication].
    Wysocka K; Kiczak J
    Reumatologia; 1977; 15(4):455-9. PubMed ID: 24871
    [No Abstract]   [Full Text] [Related]  

  • 35. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine.
    Candela M; Pansoni A; Jannino L; Menditto VG; Natalini M; Ravaglia F; Da Lio L; Scorza R; Gabrielli A; Danieli G
    Ann Ital Med Int; 2001; 16(3):170-4. PubMed ID: 11692906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha interferon in systemic sclerosis.
    Shah VM; Mangat GK; Joshi VR
    J Assoc Physicians India; 2001 Jun; 49():676-7. PubMed ID: 11584956
    [No Abstract]   [Full Text] [Related]  

  • 37. Isotretinoin in the treatment of systemic sclerosis.
    Maurice PD; Bunker CB; Dowd PM
    Br J Dermatol; 1989 Sep; 121(3):367-74. PubMed ID: 2803961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of systemic scleroderma with fucidine with regard to some free amino acids contents before and after therapy.
    Rubisz-Brzezińska J; Zebracka T; Mozdzanowska K; Mozdzanowski J
    Acta Derm Venereol; 1984; 64(3):267-70. PubMed ID: 6204494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
    J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to antifibrotic therapy and decrease of circulating BAG3 protein levels in systemic sclerosis patients with reduced forced vital capacity.
    De Marco M; Basile A; Cammarota AL; Iannone C; Falco A; Marzullo L; Rosati A; Caporali R; Turco MC; Del Papa N
    Biomed Pharmacother; 2024 May; 174():116578. PubMed ID: 38608524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.